Actively Recruiting
Natural History of Type 1 Interferonopathies: Insights From a European Cohort
Led by Imagine Institute · Updated on 2026-05-13
500
Participants Needed
32
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Type I interferonopathies are rare genetic disorders causing inflammation and affecting mainly the central nervous system, with common joint problems and occasional blood or immune system issues. These diseases often begin in childhood but can also start in adulthood and are resistant to usual immunosuppressive treatments. Researchers aim to better understand how these conditions develop over time in both children and adults to identify diagnostic and monitoring biomarkers and improve future therapies. This observational study includes patients with genetically confirmed type I interferonopathy who are part of a social security system. The study will follow patients from 2025 to 2045, collecting information to characterize disease progression, identify genotype-related immune factors, discover biomarkers for diagnosis and prognosis, and monitor treatment responses based on patient phenotypes and genotypes. Participants will be observed over many years with regular assessments to track how their condition changes and how they respond to treatments. The main focus is on understanding the natural history of the disease by reviewing clinical features, biological markers, and genetic information. This long-term follow-up will help researchers define patient subgroups and guide more personalized treatment approaches in the future.
CONDITIONS
Brief Title
Natural History of Type 1 Interferonopathies: Insights From a European Cohort
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Genetically confirmed patient with type I interferonopathy
- Patient affiliated to a social security scheme or beneficiary of such a scheme.
You will not qualify if you...
- Opposition of the patient and/or parental authority if the patient is a minor, to participation in the study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - From 2025 to 2045
Participants with genetically confirmed type I interferonopathy are observed over time to characterize disease progression and monitor treatment responses.
Trial Site Locations
Total: 32 locations
1
Medical University Innsbruck
Innsbruck, Austria
Not Yet Recruiting
2
Antwerp University Hospital
Antwerp, Belgium
Not Yet Recruiting
3
Children's Hospital Zagreb
Zagreb, Croatia
Not Yet Recruiting
4
Motol University Hospital
Prague, Czechia
Not Yet Recruiting
5
CHU d'Angers
Angers, France, 49000
Actively Recruiting
6
Hôpital de Mercy - CHR Metz Thionville
Ars-Laquenexy, France, 57530
Actively Recruiting
7
CHU de Besançon
Besançon, France, 25030
Actively Recruiting
8
CHU de Bordeaux
Bordeaux, France
Not Yet Recruiting
9
CHU Morvan
Brest, France, 29200
Actively Recruiting
10
Hôpital Femme Mère Enfant - HCL
Bron, France, 69500
Actively Recruiting
11
CHU de Dijon
Dijon, France, 21231
Not Yet Recruiting
12
Hôpitaux Nord Ouest Villefranche
Gleizé, France, 69400
Actively Recruiting
13
Hôpital Bicêtre
Le Kremlin-Bicêtre, France, 94270
Not Yet Recruiting
14
Hôpital Claude Huriez, CHU de Lille
Lille, France, 59000
Not Yet Recruiting
15
APHM Hôpitaux de Marseille
Marseille, France
Actively Recruiting
16
CHU de Montpellier
Montpellier, France, 34295
Actively Recruiting
17
CHRU Nancy
Nancy, France
Actively Recruiting
18
CHU de Nantes
Nantes, France, 44000
Actively Recruiting
19
CH Agen-Nérac
Nérac, France, 47600
Actively Recruiting
20
Hôpital de l'Archet
Nice, France, 06200
Actively Recruiting
21
Hôpital Armand Trousseau
Paris, France, 75012
Not Yet Recruiting
22
Hôpital Bichat
Paris, France, 75018
Not Yet Recruiting
23
Hôpital Robert Debré
Paris, France, 75019
Not Yet Recruiting
24
Hôpital des Enfants - CHU de Toulouse
Toulouse, France, 31300
Actively Recruiting
25
Hôpital Necker Enfants Malades
Paris, Île-de-France Region, France, 75015
Actively Recruiting
26
University of Tübingen
Tübingen, Germany
Not Yet Recruiting
27
Meyer Children's Hospital IRCCS
Florence, Italy
Not Yet Recruiting
28
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Not Yet Recruiting
29
Hospital Universitario Son Espases
Palma de Mallorca, Spain
Not Yet Recruiting
30
Karolinska University Hospital
Stockholm, Sweden
Not Yet Recruiting
31
Hacettepe İhsan Doğramacı Children's Hospital
Ankara, Turkey (Türkiye)
Actively Recruiting
32
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
Not Yet Recruiting
Research Team
M
Marie-Louise FREMOND, Pr
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here